Antibacterial effects of microbial synthesized silver-copper nanoalloys on
Escherichia coli, Burkholderia cepacia, Listeria monocytogenes and
Brucella abortus

Sheida Mohammadi1, Nima Hosseini Jazani2*, Mehri Kouhkan3, Leila Ashrafi Babaganjeh3

1Students’ Research Committee, Urmia University of Medical Sciences, Urmia, Iran
2Department of Microbiology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran
3Faculty of Pharmacology, Urmia University of Medical Sciences, Urmia, Iran

Received: September 2017, Accepted: April 2018

ABSTRACT

Background and Objectives: Bacterial resistance is an emerging public health problem worldwide. Metallic nanoparticles and nanoalloys open a promising field due to their excellent antimicrobial effects. The aim of the present study was to investigate the antibacterial effects of Ag-Cu nanoalloys, which were biosynthesized by Lactobacillus casei ATCC 39392, on some of the important bacterial pathogens, including Escherichia coli, Burkholderia cepacia, Listeria monocytogenes and Brucella abortus.

Materials and Methods: Ag-Cu nanoalloys were synthesized through the microbial reduction of AgNO3 and CuSO4 by Lactobacillus casei ATCC39392. Furthermore, they were characterized by Fourier-Transform Infrared Spectrometer (FTIR) and Field Emission Scanning Electron Microscopy (FESEM) analysis in order to investigate their chemical composition and morphological features, respectively. The minimum inhibitory and minimum bactericidal concentrations of Ag-Cu nanoalloys were determined against each strain. The bactericidal test was conducted on the surface of MHA supplemented with 1, 0.1, and 0.01 μg/µL of the synthesized nanoalloy. The antimicrobial effects of synthesized nanoalloy were compared with ciprofloxacin, ampicillin and ceftazidime as positive controls.

Results: Presence of different chemical functional groups, including N-H, C-H, C-N and C-O on the surface of Ag-Cu nanoalloys was recorded by FTIR. FESEM micrographs revealed uniformly distributed nanoparticles with spherical shape and size ranging from 50 to 100 nm. The synthesized Ag-Cu nanoalloys showed antibacterial activity against L. monocytogenes PTCC 1298, E. coli ATCC 25922 and B. abortus vaccine strain. However, no antibacterial effects were observed against B. cepacia ATCC 25416.

Conclusion: According to the findings of the present research, the microbially synthesized Ag-Cu nanoalloy demonstrated antibacterial effects on the majority of the bacteria studied even at 0.01 μg/µL. However, complementary investigations should be conducted into the safety of this nanoalloy for in vivo or systemic use.

Keywords: Escherichia coli, Burkholderia cepacia, Listeria monocytogenes, Brucella abortus, Ag-Cu nanoalloy
INTRODUCTION

Nanotechnology is a modern research field dealing with synthesis, manipulation, and use of particles the size of which ranges from 1 to 100 nm. Metal nanoparticles (NPs) are extensively employed in many different areas such as health care, cosmetics, environmental health, and medicine (1). Silver NPs (AgNPs) are increasingly utilized in medical fields due to their peculiar properties, including antibacterial, antifungal, antiviral, anti-inflammatory, anti-cancer, and anti-angiogenic agents (2). They appear to be alternative antibacterial agents because of their large surface-to-volume ratio and crystal structure. Moreover, they have the ability to overcome the problem of bacterial resistance to a wide range of antimicrobial agents such as antibiotics (3). On the other hand, it has been reported that copper and copper oxide NPs have high potential to kill bacterial cells and heal wounds (4-7).

A variety of techniques have been applied to synthesize NPs. These techniques are classified in three main groups, including chemical, physical, and bio-based methods (1). Several studies have indicated that physical and chemical methods for the synthesis of NPs use high radiations or concentrated stabilizing and reducing agents, being harmful to human and the environment. Additionally, these methods are expensive and eco-unfriendly (8-10). Accordingly, genuine attempts have been made to develop economic as well as eco-friendly methods to synthesize NPs by using living cells, including microorganisms which are not harmful to the environment (11-16). Bacteria are considered a new green factory for the bio-synthesis of metallic NPs because they have a fast growth rate and extraordinary abilities to adapt to very different environmental conditions. Furthermore, they are inexpensive and abundant in the environment and their cultivation conditions can be easily controlled (17).

Bimetallic nanoalloys are clusters with two or more metallic elements (18). They have attracted many researchers’ interest because of their specific chemical and physical properties. Bimetallic NPs, such as Platinum-Ruthenium, Copper- Palladium, Platinum - Molybdenum and Gold -Silver are some examples of nanoalloys. Many show catalytic properties. The properties and application of metallic NPs mainly depend on their size and shape. Various shapes are reported for metal NPs including bar shaped, spherical, rods, cubes, and wires, and also in the form of nanocrystals with an unpredictable symmetry (19). Like many other NPs and nanoalloys, several important properties are attributed to Ag-Cu nanoalloys. Ag-Cu nanoalloys have previously been synthesized from their metal salts by chemical co-reduction. In addition, they have shown antibacterial activity against Escherichia coli and they also showed better antimicrobial activity in comparison with Ag – only or Cu- only NPs (20). Recently the green synthesis of Ag-Cu nanoalloys using a plant extract was performed by two synthesis methods including core-shell and Janus morphologies by reversing the order of precursors. However, they did not report any antibacterial effects (21).

Escherichia coli is one of the most important causes of several types of multi - drug resistant infections. The emergence of antimicrobial resistance has threatened the therapeutic treatment of E. coli infections in recent decades. On the other hand, in the present study, E. coli was chosen as a prototype of Gram-negative bacteria (22). Listeria monocytogenes is Gram-positive, food-borne pathogen which causes fatal infections in immunocompromised patients. Several studies reported isolation of resistant strains of Listeria from different sources to several antibiotics. Also, in several studies, Listeria was used as the prototype of gram positive bacteria (23-28). Brucella abortus is one of the causative agents of human brucellosis. In recent years, a number of studies have reported reduced susceptibility of Brucella species to antibiotics or even strains with multi-drug resistance (29-32). Burkholderia cepacia complex is capable of causing several types of opportunistic infections in hospitalized patients. This microorganism shows high intrinsic resistance and is found to be one of the most resistant bacteria in the clinical settings; therefore, these infections are very difficult to treat and, in many cases, result in death (33-35).

The antibacterial effects of synthesized Ag-Cu nanoalloys were evaluated on several Gram-positive and Gram-negative bacterial strains including Staphylococcus aureus, Bacillus subtilis, Klebsiella pneumoniae, Pseudomonas aeruginosa (ATCC27853), and Acinetobacter calcoaceticus (ATCC 23055) in our previous study (36). Hence, the aim of the present study was to investigate the antibacterial effects of Ag-Cu nanoalloys, which were biosynthesized by Lactobacillus casei (ATCC 39392), on a number of other important bacterial pathogens, including E.
coli, B. cepacia, L. monocytogenes and B. abortus.

MATERIALS AND METHODS

Microorganisms. The reference species of the following bacteria were obtained from the American Type Culture Collection (ATCC) and the Persian Type Culture Collection (PTCC) at the Iranian Research Organization for Science and Technology (IROST). The bacteria included L. casei ATCC 39392, E. coli ATCC25922, B. cepacia ATCC 25416, L. monocytogenes PTCC 1298, and B. abortus vaccine strain. L. casei ATCC 39392 was employed for the biosynthesis of Ag-Cu nanoalloys, and the other bacterial strains were utilized to test the antibacterial effects of NPs which were produced.

Microbial synthesis of Ag-Cu nanoalloys. Ag-Cu nanoalloys were synthesized via the reduction of AgNO$_3$ and CuSO$_4$ salts (both from Sigma Aldrich, USA). In brief, in order to produce Ag-Cu nanoalloys, L. casei ATCC39392 was cultivated for 24 h at 30°C in MRS broth (Liofilchem, Italy) which was supplemented with Tween-80. The aqueous mixture of copper and silver salts (with the final concentration of 75% Ag and 25% Cu) was added to the flask. After the incubation period with metal salts (48 h), formation of NPs at the bottom of the flask was investigated by changing the color of the MRS broth from yellow to dark brown. Centrifugation at 3,500 rpm for 5 minutes was applied to extract the nanoparticles, and then the product was filtered and washed three times with deionized water and dried at 40°C for 4 h.

Characterization of Ag-Cu nanoalloys. The microbially synthesized Ag-Cu nanoalloys were characterized by various analytical methods, including Fourier-Transform Infrared Spectrometer (FTIR) (Thermo Nicolet Nexus 670 Model) in order to investigate the chemical composition of the synthesized nanoalloys. The spectra were scanned in the range of 500 to 4,000 cm$^{-1}$. Field Emission Scanning Electron Microscopy (FESEM) analysis was carried out to study morphological features such as the shape and size of the nanoalloys.

Antimicrobial effects: Determination of Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) of Ag-Cu nanoalloys. MICs and MBCs of Ag-Cu nanoalloys were determined for B. cepacia (ATCC 25416), L. monocytogenes (PTCC 1298), E. coli ATCC25922 and B. abortus vaccine strain. CLSI 2016 guideline for Macro dilution method was applied to evaluate the antimicrobial activity of Ag-Cu nanoalloys. Muller Hinton Broth (MHB) was utilized for the overnight cultivation of bacterial strains at 37°C. Subsequently, the bacteria were harvested after centrifugation, washed, and re-suspended in normal saline. The antibacterial effects of Ag-Cu nanoalloys were investigated in the range of 2-1.95 × 10$^{-3}$ µg/µL by preparing two-fold dilutions in the test tubes. 1.5 × 10$^6$ Colony Forming Units (C.FUs) of each isolate was added to each test tube, and the turbidity of broth media was investigated after 24 h at 37°C. MIC and MBC were considered as the lowest concentration of the Ag-Cu nanoalloys, causing no turbidity in MHB or inhibiting the growth of more than 99.9% of the initial inoculum of bacteria in MHA, respectively. MHB medium without nanoalloy and un-inoculated MHB medium were considered as positive and negative controls, respectively (37, 38). All experiments were conducted in triplicate.

Determination of MIC and MBC of ampicillin, ciprofloxacin and ceftazidime. MICs and MBCs of ampicillin, ciprofloxacin and ceftazidime (sigma) were determined by the microdilution broth method for studied bacteria according to the CSLI 2016 guideline. Microbial suspensions were prepared and the concentration was adjusted to 0.5 McFarland turbidity standard. Two-fold serial dilutions of an initial antibiotic solution in the range of 0.512- 0.0005 μg / µL were prepared in MHB. MICs and MBCs were determined as described for biosynthesized nanoalloys.

Bactericidal test. Ag-Cu nanoalloy was tested in order to investigate its bactericidal effect. The bacterial strains were cultivated on the surface of MHA supplemented with 1, 0.1, and 0.01 µg/µL of the synthesized nanoalloy. A MHA medium without nanoalloy was utilized as the negative control. Incubation was performed at 37°C for 24 h, and the number of the colonies was determined afterwards (39, 40). AgNO$_3$ and CuSO$_4$ were inserted in separate MHA plates, with the concentration of 1 µg/µL, which were used to compare these metal salts’ bactericidal
effects with Ag-Cu nanoalloy. All experiments were repeated three times, and the mean values were considered as the results.

RESULTS

Characterization of Ag-Cu nanoalloy. Color change in MRS culture medium. Synthesis of the Ag-Cu nanoalloy in broth medium was monitored by investigating color change after adding metal salts with defined concentrations to the MRS broth containing *L. casei* ATCC39392 for 24 h at 30°C. Forty-eight hours after adding AgNO$_3$ and CuSO$_4$ to the broth, its color turned from yellow to dark brown, indicating the formation of Ag-Cu nanoalloys. However, no color change was observed in the absence of the bacterial culture.

Fourier-transform infrared spectroscopy. Presence of different chemical functional groups, including N-H stretching vibrations of amines or amide linkages (strong peaks at 3100-3680 cm$^{-1}$), C-H stretching vibration of the alkenes group (small peak at 2925 cm$^{-1}$), amide bands of proteins (at 1634 cm$^{-1}$ and 1448 cm$^{-1}$), C-N stretching vibrations of aromatic and aliphatic amines (the bands observed at 1335 and 1264 cm$^{-1}$, respectively), and C-O stretching vibrations related to carboxylate and alcoholic groups (the weaker band at 1039 cm$^{-1}$) on the surface of Ag-Cu nanoalloys were recorded by FTIR. Thus it can be concluded that the biosynthesized nanoalloys are coated by proteins. In addition, the coating of nanoalloys by biomolecules stabilizes them in water and prevents them from aggregation (Fig. 1).

Field emission scanning electron microscopy. Fig. 2. shows FESEM micrographs of the biosynthesized nanoalloy and analyzes the size, shape, and distribution of the nanoparticles. It can be concluded from this figure that the size of the synthesized nanoalloys are less than 100 nm, that these nanoalloys have spherical shape, and that they are uniformly distributed.
Minimum inhibitory and minimum bactericidal concentrations of Ag-Cu nanoalloys. The synthesized Ag-Cu nanoalloys showed antibacterial activity against *L. monocytogenes* PTCC 1298, *E. coli* ATCC 25922, and *B. abortus* vaccine strain. However, no antibacterial effects were observed against *B. cepacia* ATCC 25416. Table 1 summarizes the results of MIC and MBC determination for the bacteria tested and compares these effects with some selected antibiotics.

**Bactericidal test.** The antibacterial tests were performed on the selected bacterial strains on MHA agar plates containing different concentrations of Ag-Cu nanoalloys. As shown in Table 2, 0.5, 0.1, and 0.01 μg/μL concentrations of the synthesized nanoalloys completely prevented the growth of *L. monocytogenes*. For the *B. abortus* vaccine strain and *E. coli*, 0.5 and 0.1 μg/μL concentrations of Ag-Cu nanoalloys were completely inhibitory; however, fewer than ten colonies were observed in the presence of 0.01 μg/μL for both of the abovementioned strains. No antibacterial effects were observed on *B. cepacia* in the presence of all of the concentrations tested (Table 2). AgNO₃ and CuSO₄, with equal concentrations of the nanoalloys, had no inhibitory effects on all of the bacterial strains used as controls.

Table 1. MIC and MBC of Ag-Cu nanoalloys for microorganisms tested in comparison with selected antibiotics.

| Strain            | MIC, (MBC) Ag-Cu nanoalloys μg/µL | MIC, (MBC) ciprofloxacin μg/µL | MIC, (MBC) Ampicillin μg/µL | MIC, (MBC) Ceftazidime μg/µL |
|-------------------|-----------------------------------|---------------------------------|-----------------------------|-------------------------------|
|                   | Mean ± SD                         | Mean ± SD                       | Mean ± SD                   | Mean ± SD                     |
| *L. monocytogenes*| 0.250±0, (0.250±0)                | 0.004(0.004)                    | 0.004 ± 0.0 (0.004 ± 0.0)   | Nt                            |
| PTCC 1298         |                                   |                                 |                             |                               |
| *B. abortus*      | 0.250±0, (0.250±0)                | 0.008 ± 0.0 (0.008 ± 0.0)       | Nt                          | Nt                            |
| vaccine strain    |                                   |                                 |                             |                               |
| *B. cepacia*      | - (-)                             |                                 | Nt                          | 0.032 ± 0.0 (0.32 ± 0.0)      |
| ATCC 25416        |                                   |                                 | Nt                          |                               |
| *E. coli* ATCC25922| 0.500±0, (0.250±0)                | 0.004 ± 0.0 (0.004 ± 0.0)       | 0.008 ± 0.0 (0.008 ± 0.0)   | Nt                            |

Nt: Not tested

Table 2. Number of bacterial colonies grown on MHA plates containing 0.5, 0.1 and 0.01 μg/μL of Ag-Cu nanoalloys

| Bacterial strains | Inoculum size C.F.U | No. of colonies on positive control plate | Nanoalloy concentration (NC) μg/µL |
|-------------------|---------------------|------------------------------------------|-----------------------------------|
|                   |                     |                                          | 0.5                               |
|                   |                     |                                          | 0.1                               |
|                   |                     |                                          | 0.01                              |
| *L. monocytogenes*| 10⁶                 | +++                                      | NG                                |
| PTCC 1298         |                     |                                          | NG                                |
| *B. abortus*      | 10⁶                 | +++                                      | NG                                |
| vaccine strain    |                     |                                          | +                                 |
| *B. cepacia*      | 10⁶                 | +++                                      | +++                               |
| ATCC 25416        |                     |                                          | +++                               |
| *E. coli*         | 10⁶                 | +++                                      | NG                                |
| ATCC25922         |                     |                                          | +                                 |

+<10 C.F.U
+++<100 C.F.U
++++<1000 C.F.U
+++++>1000 C.F.U
**Treatment: (AgNo3 75%, CuSo4 25%)**
DISCUSSION

Antimicrobial agents introduced thus far are synthetic, semisynthetic, or completely natural. Antibiotics, as a group of antimicrobials, are miracle drugs with selective toxicity which are usable in the human body via systemic or topical prescription. However, the misuse of antibiotics has resulted in development of multi-drug-resistant microorganisms, one of the most threatening challenges to humans, especially in health care settings. Therefore, the use of new technologies appears to be essential for designing unique effective antibiotics. Nanotechnology is a promising field which can overcome the problem of antibiotic resistance. Several metallic nanoparticles have been developed to eradicate or inhibit antibiotic-resistant bacteria. Furthermore, the microbial synthesis of nanoparticles and nanoalloys is a friendly process in both fields of environment and economy and does not use toxic chemical compounds in the synthesis procedure; however, the safety of in vivo use of these components should be considered (41). The high antibacterial effects and low toxicity of silver and copper nanoparticles have been previously demonstrated (4, 42-44).

Taner et al. (2011) reported the synthesis of Ag-Cu nanoalloys by chemical co-reduction of their metal salts in an aqueous solution with hydrazine hydrate and investigated their antibacterial effects on E. coli. They found that Ag-Cu nanoalloys have better antibacterial effects in comparison with silver or copper nanoparticles alone (20). In the present study, Ag-Cu nanoalloys were synthesized biologically, using a Lactobacillus strain, and their antibacterial effects on E. coli as well as some other clinically important bacterial strains were evaluated. Our results also revealed notable antibacterial effects of Ag-Cu nanoalloys on L. monocytogenes, E. coli and B. abortus.

Many antibacterial agents should penetrate into the bacterial cells as they interfere with intracellular functions. In Gram-negative bacteria, the outer membrane provides an additional barrier that must be traversed by antimicrobials (45). Gram-negative bacteria have shown significant variation in permeability to antibiotics; however, unlike E. coli, a number of Gram-negative bacterial species such as Burkholderia are considered “impermeable” (46). The composition of the outer membrane of Gram-negative bacteria has strong effects on its permeability to antimicrobial agents. It has been reported in several studies that the B. cepacia complex is intrinsically resistant to different classes of antibiotics. Numerous mechanisms are involved in the resistance of Burkholderia to antimicrobials; for example, the outer membrane in Burkholderia species contains a trimeric porin called Omp38. Omp38 is homologue to OmpF of E. coli, but less permeable than OmpF. This, along with other mechanisms such as the presence of multiple efflux pumps (46), may result in the resistance of Burkholderia species to many antibiotics and antimicrobial agents.

It has been indicated that AgNPs cause severe damage to the membrane and result in cytosolic leakage in B. pseudomallei which is the causative agent of melioidosis (47). In another study, carbon NPs complexed with Ag were found to have effective antimicrobial activity against some multi-drug-resistant bacteria, including B. cepacia (48). Nevertheless, to the best of our knowledge, the antibacterial effects of nanoalloys on B. cepacia have not been investigated yet. We found that Ag-Cu nanoalloys did not have any antimicrobial effects on B. cepacia (ATCC 25416). Several studies have mentioned that infections resulting from B. cepacia in individuals with underlying conditions, especially in cystic fibrosis patients, remain challenging in respect to their treatment (49). As a result, investigations into newer antibacterial agents for B. cepacia complex infections are recommended.

The MICs and MBCs of ciprofloxacin for L. monocytogenes, B. abortus and E. coli, ampicillin for L. monocytogenes and E. coli and ceftazidime for B. cepacia were compared with Ag-Cu nanoalloy in the present study. As the results of the present study showed, selected antibiotics were more effective than synthesized nanoalloy against tested microorganisms. Unlike antibiotics (50), developing resistance to NPs requires multiple simultaneous gene mutations in the same bacterium due to involvement of several simultaneous mechanisms of action of NPs. So, NPs should be considered as valuable alternatives to antibiotics which have high potential to solve the problem of the emergence of multi-drug resistant microorganisms (51). On the other hand, several characteristics including the size, charge, surface morphology, and crystal structure are significant factors that regulate the antibacterial effects of NPs (51). Improvement of synthesis methods may increase the antibacterial efficacy of the produced Ag-Cu nanoalloy by altering the above mentioned features.
In conclusion, the findings of the present research confirmed that microbially synthesized Ag-Cu nanoalloy showed notable antibacterial effects on a number of bacteria studied. However, complementary investigations should be conducted into the safety of this microbially synthesized Ag- Cu nanoalloy for in vivo or systemic usage.

ACKNOWLEDGEMENTS

This research was supported by the Deputy of Research and Technology of Urmia University of Medical Sciences, Urmia, Iran [Grant number:1394-01-42-1989].

REFERENCES

1. Iravani S, Korbekandi H, Mirmohammadi SV, Zolfaghari B. Synthesis of silver nanoparticles: chemical, physical and biological methods. Res Pharm Sci 2014; 9:385-406.
2. Chernousova S, Epple M. Silver as antibacterial agent: ion, nanoparticle, and metal. Angew Chem Int Ed Engl 2013; 52:1636-1653.
3. Zhang X-F, Liu Z-G, Shen W, Gurunathan S. Silver nanoparticles: Synthesis, characterization, properties, applications, and therapeutic approaches. Int J Mol Sci 2016; 17:E1534.
4. Chatterjee AK, Chakraborty R, Basu T. Mechanism of antibacterial activity of copper nanoparticles. Nanotechnology 2014; 25:135101.
5. Tamayo L, Azocar M, Kogan M, Riveros A, Paez M. Copper-polymer nanocomposites: An excellent and cost-effective biocide for use on antibacterial surfaces. Mater Sci Eng C Mater Biol Appl 2016; 69:1391-1409.
6. Tiwari M, Narayanan K, Thakar MB, Jagani HV, Venkata Rao J. Biosynthesis and wound healing activity of copper nanoparticles. IET Nanobiotechnol 2014; 8:230-237.
7. Ren G, Hu D, Cheng EW, Vargas-Reus MA, Reip P, Allaker RP. Characterisation of copper oxide nanoparticles for antimicrobial applications. Int J Antimicrob Agents 2009; 33:587-590.
8. Shah M, Fawcett D, Sharma S, Tripathy SK, Poinern GEJ. Green synthesis of metallic nanoparticles via biological entities. Materiales (Basel) 2015; 8:7278-7308.
9. Sathishkumar M, Sneha K, Won S, Cho C-W, Kim S, Yun Y-S. Cinnamon zeylanicum bark extract and powder mediated green synthesis of nano-crystalline silver particles and its bactericidal activity. Colloids Surf B Biointerfaces 2009; 73:332-338.
10. Kuppusamy P, Yusoff MM, Maniam GP, Govindan N. Biosynthesis of metallic nanoparticles using plant derivatives and their new avenues in pharmacological applications–An updated report. Saudi Pharm J 2016; 24: 473–484.
11. Jain D, Daima HK, Kachhwaha S, Kothari S. Synthesis of plant-mediated silver nanoparticles using papaya fruit extract and evaluation of their anti microbial activities. Dig J Nanomater Biostruc 2009; 4:557-563.
12. Singh A, Jain D, Upadhyay M, Khandelwal N, Verma H. Green synthesis of silver nanoparticles using Ar- genome mexicana leaf extract and evaluation of their antimicrobial activities. Dig J Nanomater Biostruc 2010; 5:483–489.
13. Vijayakumar M, Priya K, Nancy F, Noorlidad A, Ahmed A. Biosynthesis, characterisation and antibacterial effect of plant-mediated silver nanoparticles using Artemisia nilagirica. Ind Crops Prod 2013; 41:235-240.
14. Gan PP, Ng SH, Huang Y, Li SFY. Green synthesis of gold nanoparticles using palm oil mill effluent (POME): a low-cost and eco-friendly viable approach. Bioresour Technol 2012; 113:132-135.
15. Iravani S. Green synthesis of metal nanoparticles using plants. Green Chem 2011; 13:2638-2650.
16. Ingle A, Rai M, Gade A, Bawaskar M. Fusarium solanii: a novel biological agent for the extracellular synthesis of silver nanoparticles. J Nanopart Res 2009; 11:2079-2085.
17. Pantidos N, Horsfall LE. Biological synthesis of metallic nanoparticles by bacteria, fungi and plants. J Nanomol Nanotechnol 2014; 5:233.
18. Alvarez-Puebla RA, Bravo-Vasquez JP, Cheben P, Xu D-X, Waldron P, Fenniri H. SERS-active Ag/Au bimetallic nanoalloys on Si/SiO(x). J Colloid Interface Sci 2009; 333:237-241.
19. Sopousek J, Pinkas J, Broz P, Bursik J, Vykoukal V, Skoda D, et al. Ag-Cu colloid synthesis: bimetallic nanoparticle characterization and thermal treatment. J Nanomater 2014; Article ID 638964.
20. Taner M, Sayar N, Yulug IG, Suzer S. Synthesis, characterization and antibacterial investigation of silver–copper nanoalloys. J Mater Chem 2011; 21:13150-13154.
21. Rocha-Rocha O, Cortez-Valadez M, Hernandez-Martinez AR, Gamez-Corales R, Alvarez R, Britto-Hurado R, et al. Green synthesis of Ag-Cu nanoalloys using Opuntia ficus-indica. J Electron Mater 2017; 46:802-807.
22. Allocati N, Masulli M, Alexeyev MF, Di Ilio C. Escherichia coli in Europe: an overview. Int J Environ Res Public Health 2013; 10:6235-6254.
23. Vazquez-Boland JA, Kuhn M, Berche P, Chakraborty...
17. SheIDa MOHammadi

24. Khan SH, Badovinac VP. *Listeria monocytogenes*: a model pathogen to study antigen-specific memory CD8 T cell responses. *Semin Immunopathol* 2015; 37:301-310.

25. Yan SF, Wang W, Bai L, Hu YJ, Dong YP, Xu J, et al. Antimicrobial resistance, virulence profile, and molecular characterization of *Listeria monocytogenes* isolated from ready-to-eat food in China, 2013-2014. *Biomed Environ Sci* 2016; 29:448-452.

26. Dahshan H, Merwad AM, Mohamed TS. Potential impact of the resistance to quaternary ammonium disinfectants on the persistence of *Listeria monocytogenes* in food processing environments. *Front Microbiol* 2016; 7:638.

27. Martinez-Suarez JV, Ortiz S, Lopez-Alonso V. *Listeria* species in broiler poultry farms: Potential public health hazards. *J Microbiol Biotechnol* 2016; 26:1551-1556.

28. Aras Z, Ardic M. Occurrence and antibiotic susceptibility of *Listeria* species in turkey meats. *Korean J Food Sci Anim Resour* 2015; 35:669-673.

29. Razzaghi R, Rastegar R, Momen-Heravi M, Erami L. Antimicrobial resistance, virulence profile, and molecular biofilms. *Front Microbiol* 2016; 7:182.

30. Ilhan Z, Solmaz H, Ekin IH. In vitro antimicrobial susceptibility of *Brucella melitensis* isolates from patients with acute brucellosis in a center of Iran. *Indian J Med Microbiol* 2016; 34:342-345.

31. Abdel-Maksoud M, House B, Wasfy M, Abdel-Rahman B, Pimentel G, Roushed G, et al. In vitro antibiotic susceptibility testing of *Brucella* isolates from Egypt between 1999 and 2007 and evidence of probable rifampin resistance. *Ann Clin Microbiol Antimicrob* 2011; 11:24.

32. Khazaei Z, Najafi A, Piranfar V, Mirnejad R. Microarray-based long oligonucleotides probe designed for *Brucella Spp*. detection and identification of antibiotic susceptibility pattern. *Electron Physician* 2015; 8:2297-2303.

33. Gautam V, Singhal L, Ray P. *Burkholderia cepacia* complex: beyond *Pseudomonas* and *Acinetobacter*. *Indian J Med Microbiol* 2011; 29:4-12.

34. Mahenthiralingam E, Baldwin A, Dowson CG. *Burkholderia cepacia* complex bacteria: opportunistic pathogens with important natural biology. *J Appl Microbiol* 2008; 104:1539-1551.

35. Coutinho HD. *Burkholderia cepacia* complex: virulence characteristics, importance and relationship with cystic fibrosis. *Indian J Med Sci* 2007; 61:422-429.

36. Mohammadi S, Hosseini Jazani N, Ashrafi Babaganjeh L, Kouhkan M. Biosynthesis, characterization of Ag/Cu nanoalloy particles using *Lactobacillus casei Subsp.* casei and study of antimicrobial activities. *Int J Adv Biotechnol Res* 2017; 8:1405-1415.

37. Quinteros MA, Aliasa Martinez IM, Dalmaso PR, Paez PL. Silver nanoparticles: Biosynthesis using an ATCC reference strain of *Pseudomonas aeruginosa* and activity as broad spectrum clinical antibacterial agents. *Int J Biomatter* 2016; Article ID 5971047.

38. Camci MT, Sayar N, Yulug IG, Suzer S. Zn prolongs the stability of antibacterial Silver-Copper nanoalloys. *Biochim Biophys Acta* 2013; 1:70-77.

39. Sondi I, Salopek-Sondi B. Silver nanoparticles as antimicrobial agent: a case study on *E. coli* as a model for gram-negative bacteria. *J Colloid Interface Sci* 2004; 275:177-182.

40. Shrivastava S, Bera T, Roy A, Singh G, Ramachandrarao P, Dash D. Characterization of enhanced antibacterial effects of novel silver nanoparticles. *Nanotechnology* 2007; 18:225103.

41. Rudramurthy GR, Swamy MK, Sinniah UR, Ghase-mzadeh A. Nanoparticles: Alternatives against drug-resistant pathogenic microbes. *Molecules* 2016; 21: E836.

42. Dakal TC, Kumar A, Majumdar RS, Yadav V. Mechanistic basis of antimicrobial actions of silver nanoparticles. *Front Microbiol* 2016; 7:1831.

43. Franci G, Falanga A, Galdiero S, Palomba L, Rai M, Morelli G, et al. Silver nanoparticles as potential antibacterial agents. *Molecules* 2015; 20:8856-8874.

44. Markowska K, Grudniak AM, Wolska KI. Silver nanoparticles as an alternative strategy against bacterial biofilms. *Acta Biochim Pol* 2013; 60:523-530.

45. Delcour AH. Outer membrane permeability and antibiotic resistance. *Biochim Biophys Acta* 2009; 1794:808-816.

46. Zgurskaya HI, Lopez CA, Gnanakaran S. Permeability barrier of Gram-negative cell envelopes and approaches to bypass it. *ACS Infect Dis* 2015; 1:512-522.

47. Siritongsuk P, Hongsing N, Thammawithan S, Daduang S, Klayanongsruang S, Tuanyak J, et al. Two-phase bactericidal mechanism of silver nanoparticles against *Burkholderia pseudomallei*. *PloS One* 2016; 11:e0168098.

48. Leid JG, Ditto AJ, Knapp A, Shah PN, Wright BD, Blust R, et al. In vitro antimicrobial studies of silver carbene complexes: activity of free and nanoparticle carbene formulations against clinical isolates of pathogenic bacteria. *J Antimicrob Chemother* 2012; 67:138-148.

49. Zhou J, Chen Y, Tabibi S, Alba L, Garber E, Saiman L. Antimicrobial susceptibility and synergy studies of *Burkholderia cepacia* complex isolated from patients with cystic fibrosis. *Antimicrob Agents Chemother*
2007; 51:1085-1088.
50. Ventola CL. The antibiotic resistance crisis: part 2: management strategies and new agents. *P T* 2015; 40:344-352.
51. Wang L, Hu C, Shao L. The antimicrobial activity of nanoparticles: present situation and prospects for the future. *Int J Nanomedicine* 2017; 12:1227-1249.